(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 8.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.55%.
Bio Techne's revenue in 2026 is $1,210,811,000.On average, 17 Wall Street analysts forecast TECH's revenue for 2027 to be $201,817,120,039, with the lowest TECH revenue forecast at $191,170,444,971, and the highest TECH revenue forecast at $211,054,676,348. On average, 14 Wall Street analysts forecast TECH's revenue for 2028 to be $220,918,507,661, with the lowest TECH revenue forecast at $205,261,632,561, and the highest TECH revenue forecast at $240,646,170,287.
In 2029, TECH is forecast to generate $241,585,582,793 in revenue, with the lowest revenue forecast at $222,484,195,171 and the highest revenue forecast at $259,277,851,656.